T-CELL LYMPHOMA MARKET ANALYSIS

T-cell Lymphoma Market, by Lymphoma Type (Peripheral T-cell Lymphoma (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)), and T-cell Lymphoblastic Lymphoma), by Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others (Antiviral Therapy, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Dec 2021
Code : CMI4799
Pages :168
Formats :
Excel and PDF
Industry : Biotechnology

T-cell Lymphoma MarketSize and Trends

The global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028).

Figure 1. Global T-cell Lymphoma Market Share (%), By Region, 2021

The increasing incidence of T-cell lymphoma is expected to drive the growth of the global T-cell Lymphoma market over the forecast period.

For instance, according to an article published by the Cancer Causes Control: CCC journal in May 2019, it is estimated that non-Hodgkin lymphoma (NHL) ranks amongst the top 10 most common types of cancer with around 510,000 new cases reported globally in 2018. The same source also implies that a slight increase in incidence of NHL would be observed in the near future in several areas of the globe such as Asia, Latin America, and others. T-cell lymphoma is a type of NHL, thus growing incidence of NHL is expected to have a positive impact on global T-cell lymphoma market.